Seven Eight Capital LP Sells 8,837 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Seven Eight Capital LP lessened its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 5.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 152,511 shares of the biopharmaceutical company’s stock after selling 8,837 shares during the period. Seven Eight Capital LP owned approximately 0.05% of Amicus Therapeutics worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in FOLD. Headlands Technologies LLC acquired a new position in Amicus Therapeutics during the second quarter valued at approximately $89,000. Sage Capital Advisors llc bought a new stake in shares of Amicus Therapeutics during the 2nd quarter worth $103,000. EntryPoint Capital LLC boosted its stake in Amicus Therapeutics by 278.8% in the first quarter. EntryPoint Capital LLC now owns 13,218 shares of the biopharmaceutical company’s stock valued at $156,000 after buying an additional 9,729 shares in the last quarter. Old Well Partners LLC bought a new position in Amicus Therapeutics in the fourth quarter valued at about $180,000. Finally, Mesirow Financial Investment Management Inc. acquired a new position in Amicus Therapeutics during the first quarter worth about $225,000.

Amicus Therapeutics Trading Up 0.8 %

NASDAQ FOLD opened at $11.00 on Friday. The firm has a market capitalization of $3.26 billion, a PE ratio of -22.63 and a beta of 0.69. The business’s 50-day moving average price is $11.01 and its two-hundred day moving average price is $10.75. The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. Amicus Therapeutics, Inc. has a 12 month low of $9.02 and a 12 month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $126.67 million during the quarter, compared to the consensus estimate of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. The company’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.15) EPS. On average, analysts expect that Amicus Therapeutics, Inc. will post -0.08 EPS for the current year.

Analyst Upgrades and Downgrades

FOLD has been the topic of several research reports. JPMorgan Chase & Co. decreased their price target on shares of Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 16th. Jefferies Financial Group assumed coverage on Amicus Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Finally, Wells Fargo & Company initiated coverage on Amicus Therapeutics in a research report on Thursday, May 30th. They issued an “overweight” rating and a $18.00 target price for the company. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $17.25.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $10,382,718.34. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $11.71, for a total transaction of $87,825.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at $10,382,718.34. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Bradley L. Campbell sold 6,100 shares of the stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares of the company’s stock, valued at $8,866,540. The disclosure for this sale can be found here. Insiders have sold a total of 21,100 shares of company stock worth $226,375 over the last quarter. Company insiders own 2.20% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.